Merck inks $200 million deal for Hengrui's midstage heart disease drug
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
Wipro’s agents for Agentforce will elevate efficiency and customer satisfaction at healthcare companies
Nadda noted that TB treatment coverage in India has increased from 59% to 85%
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)
Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Nanomi's pioneering approach in drug delivery has set new benchmarks in the industry, and this award serves as a motivation to continue its mission to revolutionize healthcare
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions
Subscribe To Our Newsletter & Stay Updated